A “Universal” Flu Vaccine in Progress
Researchers from the U.S. Centers for Disease Control and Prevention
revealed in 2012 that the 2009 H1N1 influenza virus most likely ended about
284,500 people worldwide. The World Health Organization (WHO) says that
seasonal influenza, or “the flu” as it is broadly termed, ends up to
500,000 individuals every year world wide. To compare, the ACS assesses
that 580,350 people will die from various of cancer in the USA by the end
of the year.
Flu consciousness is again increased due to mut ated versions like H3N2 and
H7N9 that have appeared across the earth, leaving death in their tracks.
H7_H9, just identified that in March has already ended more than twenty in
China, with the WHO proclaiming it as “one of the most lethal” and
readily-transmitted versions of the flu.
Why is this crucial? Because it mirrors the remarkable upside possibility
in this one therapeutic area for a organization to successfully create a
new vaccine to prevent an elusive global killer.
I n o v i o Pharmaceuticals, Inc.’s (NYSE MKT: I-N-O) SynCo universal
H1N1 flu vaccine has recently been proven in clinical trials to generate
protective antibody levels similar to a current FDA-sanctioned seasonal flu
vaccine against a presently spreading influenza version. The SynCon
vaccine, joined with additional Inovio research, represent industry firsts
and prompt the company’s potential to create “the next level” in flu
vaccines, planned to shield against a variety of viral versions that are
not matched to circulating flu versions targeted by the existing
"conventional" vaccine that is generally recommended and, in some cases
required, by the government and other authoritative bodies.
In addition to the up-to-date SynCon data, former clinical research testing
Inovio’s H5N1 vaccine revealed significant immune responses against six
diverse unmatched strains of H5N1.
This might be transformational therapy as typical treatments right now only
have occasion to safeguard from three separate flu breeds in their
formulations. While there are three different types of flu viruses, they
have changed into an uncountable number of versions, meaning that unmatched
vaccines are vital in attempting to stay ahead of the virus. That’s
exactly what it looks like Inovio is passing along down the path towards
With more than 135 mill doses of flu vaccines constructed in the USA alone
this year, the revenue associations of developing a cutting-edge vaccine
are ample, to say the least.
That’s really just the start of the core proficiencies of Inovio. The
organization is also creating vaccines for other multi-billion dollar
markets like the human papilloma virus (which leads to cervical cancer),
HIV, hepatitis B and C, malaria and more. Gilead Sciences is compensating
$11.1 billion for Pharmasset Inc. and its Hep C medication in Stage two
development should give a sample of what an applicable vaccine could be
The company has just about $20 million in savings and has also just
received a $3.5 million grant from the National Institute of Allergy and
Infectious Diseases for the creation of its DNA vaccine delivery device.
Contrasting several of their cash-poor and higher valued peers, Inovio has
a stout balance sheet.
Other biotechs with reduced therapies in creation have already received a
rise in market valuation due to global flu epidemics building awareness or
because of their potential vaccine therapeutics. Inovio has started
another ascent, but still has exponential space for growth in the immediate
future as well as long-term, lending to I n o v i o's Pharmaceuticals,
Inc.’s (NYSE MKT: INO) hidden upside potential that Wall Street is only
starting to recognize.
The use of research materials issued by the author is done at your own
risk. You are encouraged to do your own research before making any
investment decision in regards to the secu rity discussed herein. The
author has not been rewarded by any entity in connection with the
disbursement of these materials. You should assume that as of the date of
this report or letter, the author, possibly along with or through our
owners, affiliates, employees and/or consultants, (cooperatively referred
to as the author) has a position in all company shares (and/or options of
the shares) covered herein that is consistent with the position set forth
in our report. In connection with INO, the author has taken a long
position. Following the disbursement of any report or letter, the author
intends to continue engaging in trnsactns in the secu rity covered herein,
and we may be long, short, and/or neutral at any time hereafter regardless
of our initial position and we preserve the right to procure or trade all
or part of our position at any time without notice. This practice could
end in our trading securities at any time before, during, and/or after the
distribution of this report.
To stop receiving these
795 Folsum St., First Floor, San Francisco, CA 94107 U.S.A.